If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
New Color-Coded Embolic with Polyzene(R)-F Coating Enhances Procedural Safety, Efficiency during Treatment of Hypervascularized Tumors and Arteriovenous Malformations NEWNAN, Ga., Dec. 31 (HSMN NewsFeed) — Against the backdrop of a flagging economy, …
Devices, Interventional, Oncology
CeloNova BioSciences, Embozene, microspheres, embolization
Posts from ‘December, 2008’
First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform
Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
SAN CARLOS, Calif., Dec. 31 (HSMN NewsFeed) — Nektar Therapeutics (Nasdaq: NKTR ) today announced that it has successfully closed the divestiture of specific Nektar pulmonary delivery assets, technology, and intellectual property to Novartis for $115 mi…
Biopharmaceuticals, Drug Delivery, Acquisitions
Nektar Therapeutics, Novartis, Tobramycin
China Medical Technologies Announces the Completion of the Sale of its HIFU Business
BEIJING, Dec. 31 (HSMN NewsFeed) — China Pathology Technologies, Inc. (the "Company") (Nasdaq: CMED ), a big China-based pharmaceutical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that…
Devices, Acquisitions
China Clinical Technologies, Chengxuan, HIFU
FDA Cardio Renal Advisory Committee to Review Daiichi Sankyo, Lilly Drug Prasugrel
TOKYO and INDIANAPOLIS, Dec. 31 (HSMN NewsFeed) — Daiichi Sankyo Company, Limited (TSE: 4568 ) and Eli Lilly and Company (NYSE: LLY ) today confirmed that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (C…
Biopharmaceuticals, Cardiology
Eli Lilly, Daiichi Sankyo, Prasugrel, acute coronary syndrome
PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
Other Strength Patches (12.5, 25, Seventy five and 100 mcg/hr) Not Affected RARITAN, N.J., Dec. 31 (HSMN NewsFeed) — PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., said today that one lot of 50 microgram/hour (mcg/hr) DURAGESIC® (fen…
Biopharmaceuticals, Drug Delivery, Product Recall
PriCara, Ortho-McNeil-Janssen Pharmaceuticals, DURAGESIC, fentanyl transdermal
Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
Product to be Launched in the U.S. in the Second Quarter of 2009 LAVAL, QC, Dec. 31 (HSMN NewsFeed) - Labopharm Inc. (TSX: DDS ; NASDAQ: DDSS ) today announced that RYZOLT(TM) (tramadol HCl extended release tablets), Labopharm’s once-daily formulation…
Biopharmaceuticals, FDA
Labopharm, tramadol, RYZOLT
FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B and Hepatitis C
Advanced test for increased blood safety is first to add the detection of HIV- 1 Group O RNA and HIV-2 RNA PLEASANTON, Calif., Dec. 31 (HSMN NewsFeed) — The United States Food & Drug Administration (FDA) today approved a new nucleic acid test from Ro…
Diagnostics, FDA
Roche Group, TaqScreen MPX
U.S. Navy Requested Operations Trial on FDA Hold
CAMBRIDGE, Mass., Dec. 30 (HSMN NewsFeed) — Biopure Corporation (Nasdaq: BPUR ) announced today that the Food and Drug Administration has advised the U.S. Naval Clinical Research Center ("NMRC") by letter that it may not initiate a clinical tri…
Biopharmaceuticals
Biopure, Hemopure
GlaxoSmithKline Reduces Minimum Delicate Condition and Extends Delicate Offer To Acquire Genelabs Technologies, Inc.
LONDON, Dec. Thirty (HSMN NewsFeed) — GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that it has reduced the minimum delicate condition and extended its previously announced tender offer to purchase all of the fantastic shares of common stock of Genela…
Biopharmaceuticals, Mergers & Acquisitions
GlaxoSmithKline, Genelabs Technologies
Salient Surgical Technologies, Inc. Completes Move to New Corporate Headquarters
New Construction Includes Training, Manufacturing Facilities PORTSMOUTH, NH–Dec 30, 2008 — Salient Surgical Technologies, Inc., a privately held clinical technology company that develops and markets advanced energy devices for use in surgical procedure…
Devices
Salient Surgical Technologies, Transcollation
